Compare ALNT & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALNT | XNCR |
|---|---|---|
| Founded | 1962 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 881.9M |
| IPO Year | 1995 | 2013 |
| Metric | ALNT | XNCR |
|---|---|---|
| Price | $62.43 | $11.44 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 10 |
| Target Price | ★ $64.50 | $22.33 |
| AVG Volume (30 Days) | 174.4K | ★ 821.7K |
| Earning Date | 03-05-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.20% | N/A |
| EPS Growth | ★ 67.09 | 65.36 |
| EPS | ★ 1.32 | N/A |
| Revenue | ★ $554,478,000.00 | $125,576,000.00 |
| Revenue This Year | $7.53 | N/A |
| Revenue Next Year | $6.81 | $11.88 |
| P/E Ratio | $46.60 | ★ N/A |
| Revenue Growth | 4.62 | ★ 13.65 |
| 52 Week Low | $19.25 | $6.92 |
| 52 Week High | $70.00 | $18.69 |
| Indicator | ALNT | XNCR |
|---|---|---|
| Relative Strength Index (RSI) | 47.13 | 43.39 |
| Support Level | $59.24 | $10.92 |
| Resistance Level | $68.14 | $12.87 |
| Average True Range (ATR) | 3.32 | 0.74 |
| MACD | -0.09 | 0.03 |
| Stochastic Oscillator | 35.13 | 20.79 |
Allient Inc, formerly Allied Motion Technologies Inc designs, manufactures, and sells precision and specialty motion control components and systems. The firm primarily caters to the vehicle, medical, aerospace and defense, and electronics and industrial, pumps, and robotics sectors. It mainly operates and sells across the United States, Canada, South America, Europe, and Asia. Its products and solutions include nano precision positioning systems, servo control systems, motion controllers, digital servo amplifiers and drives, brushless servo, torque, and coreless motors, brush motors, integrated motor drives, gear motors, gearing, incremental and absolute optical encoders, active (electronic) and passive (magnetic) filters for power quality and harmonic issues.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.